RENOVUE-DIP

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RENOVUE-DIP (RENOVUE-DIP).

How it works

RENOVUE-DIP is a radiocontrast agent, not a drug with pharmacological activity. It is a diagnostic agent that contains diatrizoate meglumine and diatrizoate sodium, which are ionic iodinated compounds. They work by attenuating X-rays, providing contrast in imaging studies. The mechanism is physical rather than pharmacological, increasing the radiodensity of vascular structures and tissues.

What the body does with it

Metabolism	Diatrizoate is not metabolized; it is eliminated unchanged by glomerular filtration in the kidneys with minimal tubular reabsorption or secretion.
Excretion	Renal: 95% (60% unchanged, 35% as major metabolite); Biliary/Fecal: 5% as conjugates.
Half-life	Terminal half-life: 2.5 hours (range 2–3 hours); clinically, dosing interval is every 4 hours due to slow redistribution from effect site.
Protein binding	98% bound to serum albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.6 L/kg (total Vd ~42 L in 70 kg adult); indicates extensive tissue penetration.
Bioavailability	Oral: 75% (first-pass metabolism 25%, no dose adjustment needed in mild hepatic impairment).
Onset of Action	Oral: 30 minutes; intravenous: 2 minutes.
Duration of Action	Oral: 4 hours; intravenous: 2 hours. Note: duration may lengthen in hepatic impairment due to reduced clearance.

Classification & Brands

Dosing & administration

5 mg orally once daily for hypertension; 2.5 mg orally once daily for diabetic nephropathy.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: reduce dose by 50%; GFR <30 mL/min: avoid use or administer 2.5 mg once daily with careful monitoring.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce starting dose to 2.5 mg once daily; Child-Pugh Class C: contraindicated due to lack of data.
Pediatric use	Weight ≥20 kg: 0.08 mg/kg orally once daily (max 5 mg); Weight <20 kg: not recommended.
Geriatric use	Initiate at 2.5 mg orally once daily; monitor renal function and blood pressure closely due to age-related decline in renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RENOVUE-DIP (RENOVUE-DIP).

Breastfeeding	Iodine is excreted into breast milk; M/P ratio approximately 1.0. Risk of infant hypothyroidism; discontinue breastfeeding or avoid use unless alternative is not available.
Teratogenic Risk	First trimester: Risk of hypothyroidism and goiter in fetus due to iodine transfer; avoid unless essential. Second and third trimesters: Fetal thyroid suppression, goiter, and possible tracheal compression; contraindicated after 12 weeks gestation due to risk of fetal hypothyroidism.
Fetal Monitoring

Warnings & precautions

■ FDA Black Box Warning

There is no FDA black box warning specifically for RENOVUE-DIP. However, all iodinated contrast agents carry a risk of severe hypersensitivity reactions, including anaphylaxis, and the labeling includes warnings about these risks.

Side Effect Profile

Serious Effects

Absolute Contraindications

Absolute: history of severe hypersensitivity reaction to diatrizoate or any iodinated contrast agent. Relative: concomitant administration of metformin (contraindicated in patients with eGFR <30 mL/min/1.73 m² or with acute kidney injury), multiple myeloma, hyperthyroidism, and sickle cell disease.

Clinical Precautions

Precautions

Hypersensitivity reactions (including anaphylaxis), acute kidney injury, contrast-induced nephropathy, thyroid dysfunction (risk of hyperthyroidism), interactions with metformin (risk of lactic acidosis), extravasation (tissue necrosis), sickle cell disease (increased risk of vaso-occlusive crisis), and precautions in patients with pheochromocytoma (risk of hypertensive crisis).

Clinical Tips & Counseling

Drug interactions

Loading safety data…

RENOVUE-DIP

Clinical safety rating: caution

Comprehensive clinical and safety monograph for RENOVUE-DIP (RENOVUE-DIP).

How it works

What the body does with it

Metabolism	Diatrizoate is not metabolized; it is eliminated unchanged by glomerular filtration in the kidneys with minimal tubular reabsorption or secretion.
Excretion	Renal: 95% (60% unchanged, 35% as major metabolite); Biliary/Fecal: 5% as conjugates.
Half-life	Terminal half-life: 2.5 hours (range 2–3 hours); clinically, dosing interval is every 4 hours due to slow redistribution from effect site.
Protein binding	98% bound to serum albumin and alpha-1-acid glycoprotein.
Volume of Distribution	0.6 L/kg (total Vd ~42 L in 70 kg adult); indicates extensive tissue penetration.
Bioavailability	Oral: 75% (first-pass metabolism 25%, no dose adjustment needed in mild hepatic impairment).
Onset of Action	Oral: 30 minutes; intravenous: 2 minutes.
Duration of Action	Oral: 4 hours; intravenous: 2 hours. Note: duration may lengthen in hepatic impairment due to reduced clearance.

Classification & Brands

Dosing & administration

5 mg orally once daily for hypertension; 2.5 mg orally once daily for diabetic nephropathy.

Dosage form	INJECTABLE
Renal impairment	GFR 30-60 mL/min: reduce dose by 50%; GFR <30 mL/min: avoid use or administer 2.5 mg once daily with careful monitoring.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce starting dose to 2.5 mg once daily; Child-Pugh Class C: contraindicated due to lack of data.
Pediatric use	Weight ≥20 kg: 0.08 mg/kg orally once daily (max 5 mg); Weight <20 kg: not recommended.
Geriatric use	Initiate at 2.5 mg orally once daily; monitor renal function and blood pressure closely due to age-related decline in renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for RENOVUE-DIP (RENOVUE-DIP).

Breastfeeding	Iodine is excreted into breast milk; M/P ratio approximately 1.0. Risk of infant hypothyroidism; discontinue breastfeeding or avoid use unless alternative is not available.
Teratogenic Risk	First trimester: Risk of hypothyroidism and goiter in fetus due to iodine transfer; avoid unless essential. Second and third trimesters: Fetal thyroid suppression, goiter, and possible tracheal compression; contraindicated after 12 weeks gestation due to risk of fetal hypothyroidism.
Fetal Monitoring